Home > Insider Trading > Filing (0001213900-25-010193)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
2028614	Drugs Made In America Acquisition Corp.	DMAA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1927032	Lynn Stockwell	C/O Drugs Made In America Acqstn Corp. 1 East Broward Boulevard, Suite 700 Fort Lauderdale FL 33301	Ceo And Executive Cob	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2025-01-29	400,000	$0.00	10,257	No	4	P	Indirect	See footnote
Ordinary Shares	Disposition	2025-01-29	400,000	$0.00	9,857,143	No	4	J	Indirect	See footnote
Ordinary Shares	Disposition	2025-01-29	5,698,363	$0.00	4,158,780	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	J	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Rights to receive ordinary shares	Acquisiton	2025-01-29	400,000	$0.00	400,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
400,000			No	4	P	Indirect

Footnotes

Reflects the 400,000 private units owned by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $4,000,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
As of the Transaction Date, the sponsor transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
As of the Transaction Date, pursuant to share transfer agreements, the sponsor transferred an aggregate of 5,698,363 ordinary shares for consideration ranging from no consideration to $1.50 per share.
The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.